FDA revised the authorizations for two monoclonal antibody treatments

The FDA says they made this decision because data shows the treatments are highly unlikely to work against the Omicron variant.

The Omicron variant is the dominate variant in the US right now.

A couple of monoclonal antibody treatments are not as effective against the Omicron variant, according to the FDA.

That's why the decision was made to limit it's use to a patient who has likely been infected with COVID-19 or exposed to a variant that is susceptible to these treatments.

It's also the antibody treatment now most recommended as it remains active against the Omicron variant.

doctors say say recently they have seen a significant amount of people coming in to get tested.

Click Here for more stories